Categories: News

Torus and Aareon Collaborate on Housing Management Solution

Following an exhaustive review of the solutions on offer, Torus Group has selected the QL system from Aareon (www.aareon.co.uk) as the single, integrated system to underpin their business. Formed in April 2015 when Helena Partnerships and Golden Gates Housing Trust joined forces, North West based housing and regeneration group Torus now owns and manages more than 22,000 homes.The decision to select Aareon UK systems led to a complex project to migrate the businesses from multiple…

Source: RealWire

user

Share
Published by
user
7 years ago

Recent Posts

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…

2 hours ago

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…

2 hours ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…

2 hours ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…

2 hours ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…

2 hours ago